Patients with both Clostridiodes difficile infection and inflammatory bowel disease showed improvement after fecal microbiota transplantation, Jessica Allegretti, MD, director of the FMT program at Brigham and Women’s Hospital, said during a presentation at Digestive Disease Week. The ICON study took place at four sites across the US. Results for FMT in C. dif alone
As many as 45% of patients with gastroesophageal reflux disease (GERD) still have symptoms after receiving a once-daily proton pump inhibitor (PPI) therapy. A recent study by Jason Abdallah and colleagues at MetroHealth Medical Center, Case Western Reserve University School of Medicine, utilized survey, pH, and other data. Although a small trial, the findings showed
Awareness of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) is low among Americans who have risks associated with the diseases, according to a survey presented at the NASH Summit in Boston. Many clinical trials are currently underway regarding pharmacologic interventions in an area where diet and lifestyle are failing to curb rising incidence
FMT (or “stool transplant”) reduced hospital stays and hospital costs for patients with recurrent C. difficile infection
Many alternative medicine claims unproven, ineffective for celiac disease
In a study of 500 alternative medicine providers, a significant number advertised tests or treatments for celiac disease with claims that are either false or unproven, according to Benjamin Lebwohl, MD, director of clinical research at Columbia University’s Celiac Disease Center. See the Reuters Article referencing The American Journal of Gastroenterology article here.
We understand that the microbiome has emerged as an important consideration in clinical science, and this includes extension into the important world of oncology. The role of the microbiome in cancer is not just limited to causation and cancer risk. We now known that the microbiome modifies immune responses to tumors. It influences the clinical
